First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics

Szeto HH · British Journal of Pharmacology

Reviews how SS-31 selectively targets the inner mitochondrial membrane, binds cardiolipin electrostatically and hydrophobically, prevents cytochrome c peroxidase conversion, and preserves cristae and oxidative phosphorylation across animal disease models.

Population

Narrative review of SS-peptide pharmacology and development

Intervention

n/a

Comparator

n/a

Limitations

Written by the peptide's inventor; predates the later null phase 2/3 trials in heart failure and mitochondrial myopathy.